SS&C Technologies (SSNC) Q4 2025 earnings review
Core Engines Fire, But 'Growth' Segments Misfire
SS&C delivered a solid Q4 with Adjusted Revenue growing 8.1% and Adjusted EPS surging 18.2%. The story, however, is one of extreme divergence. The core fund administration (GlobeOp) and retirement (GIDS) businesses are accelerating, fueled by private credit demand and a massive Australian lift-out. Conversely, the segments pitched as future growth drivers—Healthcare and Intelligent Automation—collapsed, shrinking 14% and 7% respectively. Management's 2026 guidance implies steady sailing (5.1% organic growth), but the volatility in newer segments raises questions about execution beyond the core moat.
🐂 Bull Case
The GIDS segment (Retirement) accelerated massively to 13.2% organic growth in Q4, up from 9.0% in Q3. The Australian lift-out (Insignia Financial) is fully ramping and providing a durable tailwind.
Operating Cash Flow jumped 25.7% in FY25 to $1.74B. Management is aggressively returning this to shareholders, buying back 3.7 million shares in Q4 alone. The business remains incredibly capital efficient.
🐻 Bear Case
Management talks extensively about 'AI Agents' and 'Customer Zero,' yet the Intelligent Automation segment (home to Blue Prism) contracted 7.0% organically in Q4. The hype is not yet showing up in the numbers.
Healthcare organic revenue collapsed 14.0% in Q4 after growing 3.1% in Q3. Management cites 'lumpiness,' but a double-digit decline suggests competitive losses or severe execution issues.
⚖️ Verdict: 🟢
Bullish. Despite the ugly drops in Healthcare and Automation, the sheer size and acceleration of the core GlobeOp and GIDS businesses (+9-13% growth) more than compensate. The valuation remains grounded, and the cash flow supports aggressive buybacks.
Key Themes
GIDS & The Australian Lift-Out
Accelerating. The Retirement (GIDS) business is on fire, posting 13.2% organic growth in Q4 (vs 2.9% in Q2). This is driven by the massive Insignia Financial lift-out in Australia going live. This is a multi-year tailwind that provides high-visibility recurring revenue.
Intelligent Automation Reverses Course
Reversing. The Intelligent Automation segment (Blue Prism) fell 7.0% organically in Q4, a sharp reversal from +2.9% in Q3. This directly contradicts the management narrative that SS&C is a leader in 'Agentic AI.' While internal use ('Customer Zero') saves costs, external sales are struggling.
GlobeOp Resilience
Stable/Strong. GlobeOp (Fund Admin) remains the bedrock, delivering 9.6% organic growth in Q4. Private credit and alternative asset demand remains insatiable, and SS&C is capturing the lion's share of complex fund administration mandates.
Healthcare Segment Collapse
Reversing. Healthcare organic revenue dropped 14.0% in Q4. While management often describes this business as 'lumpy' due to large license deals, a drop of this magnitude is a red flag for the DomaniRx platform's adoption curve.
Intralinks Recovery is Slow
Stable. Intralinks grew 2.6% organically in Q4. While positive (vs negative earlier in the year), it confirms that the M&A market recovery is tepid. This high-margin business is not yet a tailwind.
Shareholder Returns
Accelerating. SS&C returned $384M to shareholders in Q4 alone. For the full year, they allocated over $1B to buybacks (12.3 million shares). The Board is clearly prioritizing buybacks over debt paydown (leverage 2.8x), signaling confidence in the stock's value.
Other KPIs
Stable. Up 20 bps YoY. Despite wage inflation, SS&C maintains elite margins, partly due to internal automation (Blue Prism) saving hundreds of millions in costs.
Accelerating. Up 25.7% YoY. This cash generation capability is the primary funding source for the aggressive buyback strategy.
Stable. Down slightly from 2.89x a year ago. Management remains comfortable with leverage in the high 2s/low 3s, leaving room for M&A if targets arise.
Guidance
Stable. The midpoint implies ~7.4% reported growth. Organic growth guided at ~5.1%, consistent with FY25 performance (4.8%).
Accelerating. Midpoint represents ~11.7% growth over FY25 ($6.14). This outpaces revenue growth, driven by margin expansion and share count reduction from buybacks.
Stable. Guidance aligns with the Q4 run-rate (5.3%), suggesting management does not expect the weakness in Healthcare/Automation to drag down the aggregate performance of GlobeOp/GIDS.
Stable. Midpoint implies roughly flat to slight growth (+2%) vs FY25's strong $1,745M result.
Key Questions
Blue Prism Contraction
Intelligent Automation organic revenue dropped 7% in Q4 despite the intense focus on AI. Is this a structural churn issue with legacy Blue Prism clients, and when does the 'AI Agent' revenue actually materialize?
Healthcare Visibility
With Healthcare swinging from +3% to -14% in a single quarter, what visibility do you actually have into this segment for FY26? Is the lumpiness masking lost mandates?
M&A vs. Buybacks
You spent over $1B on buybacks in 2025. With leverage at 2.8x, is the M&A pipeline dry, or do you view your own stock as significantly cheaper than private market assets?